Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides

Journal of Medicinal Chemistry

Volumn 57, Issue 13, 2014, Pages 5829-5834

  Hegemann, Julian D ^a   De Simone, Mariarosaria ^b,c,f   Zimmermann, Marcel ^a   Knappe, Thomas A ^a,g   Xie, Xiulan ^a   Di Leva, Francesco Saverio ^d   Marinelli, Luciana ^d   Novellino, Ettore ^d   Zahler, Stefan ^e   Kessler, Horst ^b,c   Marahiel, Mohamed A ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF MUNICH   (Germany)

^f CNR   (Italy)

^g ASCENDIS PHARMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; CILENGITIDE; CYCLOPEPTIDE; INTEGRIN; MICROCIN J25; TIROFIBAN; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; IC 50; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING; PROTEIN STRUCTURE;

BACTERIOCINS; CELL ADHESION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDES; PROTEIN CONFORMATION; SNAKE VENOMS;

EID: 84904336652     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5004478     Document Type: Article

References (40)

1. Sato, A. K.; Viswanathan, M.; Kent, R. B.; Wood, C. R. Therapeutic peptides: technological advances driving peptides into development Curr. Opin. Biotechnol. 2006, 17, 638-642 (Pubitemid 44791908)
2. Antosova, Z.; Mackova, M.; Kral, V.; Macek, T. Therapeutic application of peptides and proteins: parenteral forever? Trends. Biotechnol. 2009, 27, 628-635
3. Pazgier, M.; Liu, M.; Zou, G.; Yuan, W.; Li, C.; Li, C.; Li, J.; Monbo, J.; Zella, D.; Tarasov, S. G.; Lu, W. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 4665-4670
4. Young, T. S.; Young, D. D.; Ahmad, I.; Louis, J. M.; Benkovic, S. J.; Schultz, P. G. Evolution of cyclic peptide protease inhibitors Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 11052-11056
5. Ji, Y.; Majumder, S.; Millard, M.; Borra, R.; Bi, T.; Elnagar, A. Y.; Neamati, N.; Shekhtman, A.; Camarero, J. A. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide J. Am. Chem. Soc. 2013, 135, 11623-11633
6. Knappe, T. A.; Manzenrieder, F.; Mas-Moruno, C.; Linne, U.; Sasse, F.; Kessler, H.; Xie, X.; Marahiel, M. A. Introducing lasso peptides as molecular scaffolds for drug design: engineering of an integrin antagonist Angew. Chem., Int. Ed. 2011, 50, 8714-8717
7. Poth, A. G.; Chan, L. Y.; Craik, D. J. Cyclotides as grafting frameworks for protein engineering and drug design applications Biopolymers 2013, 100, 480-491
8. Chan, L. Y.; Gunasekera, S.; Henriques, S. T.; Worth, N. F.; Le, S. J.; Clark, R. J.; Campbell, J. H.; Craik, D. J.; Daly, N. L. Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds Blood 2011, 118, 6709-6717
9. Mas-Moruno, C.; Rechenmacher, F.; Kessler, H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation Anti-Cancer Agents Med. Chem. 2010, 10, 753-768
10. Biron, E.; Chatterjee, J.; Ovadia, O.; Langenegger, D.; Brueggen, J.; Hoyer, D.; Schmid, H. A.; Jelinek, R.; Gilon, C.; Hoffman, A.; Kessler, H. Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues Angew. Chem., Int. Ed. 2008, 47, 2595-2599
11. Conibear, A. C.; Bochen, A.; Rosengren, K. J.; Stupar, P.; Wang, C.; Kessler, H.; Craik, D. J. The cyclic cystine ladder of theta-defensins as a stable, bifunctional scaffold: a proof-of-concept study using the integrin-binding RGD motif ChemBioChem 2014, 15, 451-459
12. Salomon, R. A.; Farias, R. N. Microcin 25, a novel antimicrobial peptide produced by Escherichia coli J. Bacteriol. 1992, 174, 7428-7435
13. Hegemann, J. D.; Zimmermann, M.; Xie, X.; Marahiel, M. A. Caulosegnins I-III: a highly diverse group of lasso peptides derived from a single biosynthetic gene cluster J. Am. Chem. Soc. 2013, 135, 210-222
14. Hegemann, J. D.; Zimmermann, M.; Zhu, S.; Klug, D.; Marahiel, M. A. Lasso peptides from proteobacteria: genome mining employing heterologous expression and mass spectrometry Biopolymers 2013, 100, 527-542
15. Zimmermann, M.; Hegemann, J. D.; Xie, X.; Marahiel, M. A. The astexin-1 lasso peptides: biosynthesis, stability, and structural studies Chem. Biol. 2013, 20, 558-69
16. Hegemann, J. D.; Zimmermann, M.; Zhu, S.; Steuber, H.; Harms, K.; Xie, X.; Marahiel, M. A. Xanthomonins I-III: a new class of lasso peptides with a seven-residue macrolactam ring Angew. Chem., Int. Ed. 2014, 53, 2230-2234
17. Yan, K. P.; Li, Y.; Zirah, S.; Goulard, C.; Knappe, T. A.; Marahiel, M. A.; Rebuffat, S. Dissecting the maturation steps of the lasso peptide microcin J25 in vitro ChemBioChem 2012, 13, 1046-52
18. Maksimov, M. O.; Pelczer, I.; Link, A. J. Precursor-centric genome-mining approach for lasso peptide discovery Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 15223-15228
19. Maksimov, M. O.; Link, A. J. Discovery and characterization of an isopeptidase that linearizes lasso peptides J. Am. Chem. Soc. 2013, 135, 12038-12047
20. Pavlova, O.; Mukhopadhyay, J.; Sineva, E.; Ebright, R. H.; Severinov, K. Systematic structure-activity analysis of microcin J25 J. Biol. Chem. 2008, 283, 25589-25595
21. Knappe, T. A.; Linne, U.; Robbel, L.; Marahiel, M. A. Insights into the biosynthesis and stability of the lasso peptide capistruin Chem. Biol. 2009, 16, 1290-1298
22. Pan, S. J.; Link, A. J. Sequence diversity in the lasso peptide framework: discovery of functional microcin J25 variants with multiple amino acid substitutions J. Am. Chem. Soc. 2011, 133, 5016-5023
23. Avraamides, C. J.; Garmy-Susini, B.; Varner, J. A. Integrins in angiogenesis and lymphangiogenesis Nat. Rev. Cancer 2008, 8, 604-617
24. Desgrosellier, J. S.; Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 2010, 10, 9-22
25. Goodman, S. L.; Picard, M. Integrins as therapeutic targets Trends Pharmacol. Sci. 2012, 33, 405-412
26. Kapp, T. G.; Rechenmacher, F.; Sobahi, T. R.; Kessler, H. Integrin modulators: a patent review Expert Opin. Ther. Pat. 2013, 23, 1273-1295
27. Dechantsreiter, M. A.; Planker, E.; Mathä, B.; Lohof, E.; Hölzemann, G.; Jonczyk, A.; Goodman, S. L.; Kessler, H. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists J. Med. Chem. 1999, 42, 3033-3040 (Pubitemid 29384038)
28. Aumailley, M.; Gurrath, M.; Müller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 FEBS Lett. 1991, 291, 50-54
29. Gurrath, M.; Müller, G.; Kessler, H.; Aumailley, M.; Timpl, R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides Eur. J. Biochem. 1992, 210, 911-921 (Pubitemid 23015792)
30. Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αVβ3 antagonists J. Am. Chem. Soc. 1996, 118, 7461-7472 (Pubitemid 26279800)
31. Chatterjee, J.; Ovadia, O.; Zahn, G.; Marinelli, L.; Hoffman, A.; Gilon, C.; Kessler, H. Multiple N-methylation by a designed approach enhances receptor selectivity J. Med. Chem. 2007, 50, 5878-5881
32. Marinelli, L.; Lavecchia, A.; Gottschalk, K. E.; Novellino, E.; Kessler, H. Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design J. Med. Chem. 2003, 46, 4393-4404 (Pubitemid 37238743)
33. Mas-Moruno, C.; Beck, J. G.; Doedens, L.; Frank, A. O.; Marinelli, L.; Cosconati, S.; Novellino, E.; Kessler, H. Increasing αvβ3 selectivity of the anti-angiogenic drug cilengitide by N-methylation Angew. Chem., Int. Ed. 2011, 50, 9496-9500
34. Solbiati, J. O.; Ciaccio, M.; Farias, R. N.; Gonzalez-Pastor, J. E.; Moreno, F.; Salomon, R. A. Sequence analysis of the four plasmid genes required to produce the circular peptide antibiotic microcin J25 J. Bacteriol. 1999, 181, 2659-2662 (Pubitemid 29181598)
35. Solbiati, J. O.; Ciaccio, M.; Farias, R. N.; Salomon, R. A. Genetic analysis of plasmid determinants for microcin J25 production and immunity J. Bacteriol. 1996, 178, 3661-3663 (Pubitemid 26179650)
36. Frank, A. O.; Otto, E.; Mas-Moruni, C.; Schiller, H. B.; Marinelli, L.; Cosconati, S.; Bochen, A.; Vossmeyer, D.; Zahn, G.; Stragies, R.; Novellino, E.; Kessler, H. Conformational control of integrin-subtype selectivity in isoDGR peptide motifs: a biological switch Angew. Chem., Int. Ed. 2010, 49, 9278-9281
37. Bennett, J. S. Structural biology of glycoprotein IIb-IIIa Trends Cardiovasc. Med. 1996, 6, 31-36
38. Xiong, J.-P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Arnaout, M. A. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand Science 2002, 296, 151-155 (Pubitemid 34280076)
39. Marinelli, L.; Meyer, A.; Heckmann, D.; Lavecchia, A.; Novellino, E.; Kessler, H. Ligand binding analysis for human α5β1 integrin: strategies for designing new α5β1 integrin antagonists J. Med. Chem. 2005, 48, 4204-4207 (Pubitemid 40884920)
40. Heckmann, D.; Meyer, A.; Marinelli, L.; Zahn, G.; Strategies, R.; Kessler, H. Probing integrin selectivity: rational design of highly active and selective ligands for the alpha5beta1 and alphavbeta3 integrin receptor Angew. Chem., Int. Ed. 2007, 46, 3571-3574 (Pubitemid 46973460)